Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Results of rights offering? where is it?

<< Previous

Bullboard Posts

Next >>

Comment by quicksilver545on May 01, 2023 8:10pm

74 Views

Post# 35424029

RE:Results of rights offering? where is it?

Last press release said the rights offering will close on or before May 3, so I would look for a news release around then. It can take a few days to a week to collect all subscriptions and determine oversubscriptions. I just signed up via the additional subscription units as I would like the warrants, and I highly suspect this won't be fully subscribed given the sinking stock price. But we are leveraged well if the DMT trials show promise.

<< Previous

Bullboard Posts

Next >>

Get a better understanding of the psychology of options trading